The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity

Diabetes Obesity and Metabolism, Год журнала: 2020, Номер 23(3), С. 754 - 762

Опубликована: Дек. 3, 2020

To investigate the effects of once-weekly subcutaneous (s.c.) semaglutide 2.4 mg on gastric emptying, appetite, and energy intake in adults with obesity.A double-blind, parallel-group trial was conducted 72 obesity, randomized to s.c. (dose-escalated mg) or placebo for 20 weeks. Gastric emptying assessed using paracetamol absorption following a standardized breakfast. Participant-reported appetite ratings Control Eating Questionnaire (CoEQ) responses were assessed, measured during ad libitum lunch.The area under concentration-time curve (AUC) 0 5 hours after meal (AUC0-5h,para ; primary endpoint) increased by 8% (P = 0.005) versus at week (non-significant when corrected body weight; P 0.12). No effect seen AUC0-1h,para , maximum observed concentration, time concentration. Ad 35% lower (1736 2676 kJ; estimated treatment difference -940 <0.0001). Semaglutide reduced hunger prospective food consumption, fullness satiety compared (all <0.02). The CoEQ indicated better control eating fewer/weaker cravings <0.05). Body weight 9.9% 0.4% placebo. Safety consistent known profile semaglutide.In suppressed improved eating, cravings, There no evidence delayed 20, indirectly via absorption.

Язык: Английский

---

Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis

BMJ, Год журнала: 2024, Номер unknown, С. e076410 - e076410

Опубликована: Янв. 29, 2024

Abstract Objective To evaluate the comparative efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on glycaemic control, body weight, lipid profile in adults with type 2 diabetes. Design Systematic review network meta-analysis. Data sources PubMed, Web Science, Cochrane Central Register Controlled Trials (CENTRAL), Embase from database inception to 19 August 2023. Eligibility criteria for selecting studies Eligible randomised controlled trials enrolled diabetes who received GLP-1RA treatments compared effects placebo or any drug, a follow-up duration at least 12 weeks. crossover design, non-inferiority comparing other drug classes without group, using withdrawn drugs, non-English were deemed ineligible. Results 76 eligible involving 15 drugs 39 246 participants included this meta-analysis; all subsequent estimates refer comparison placebo. All GLP-1RAs effectively lowered haemoglobin A 1c fasting plasma glucose concentrations. Tirzepatide induced largest reduction concentrations (mean difference −2.10% (95% confidence interval −2.47% −1.74%), surface under cumulative ranking curve 94.2%; high evidence), (−3.12 mmol/L (−3.59 −2.66), 97.2%; confidence), proved most effective control. Furthermore, shown have strong benefits weight management patients CagriSema (semaglutide cagrilintide) resulted highest loss −14.03 kg −17.05 −11.00); followed by tirzepatide (−8.47 (−9.68 −7.26); confidence). Semaglutide was lowering concentration low density lipoprotein (−0.16 (−0.30 −0.02)) total cholesterol (−0.48 (−0.84 −0.11)). Moreover, study also raises awareness gastrointestinal adverse events GLP-1RAs, concerns about are especially warranted dose administration. Conclusions efficacious treating Compared placebo, control reducing significantly improved diabetes, performing best loss. The results prompt administration, regarding events. registration PROSPERO CRD42022342845.

Язык: Английский

---

Relationship between perioperative semaglutide use and residual gastric content: A retrospective analysis of patients undergoing elective upper endoscopy

Journal of Clinical Anesthesia, Год журнала: 2023, Номер 87, С. 111091 - 111091

Опубликована: Март 2, 2023

Язык: Английский

---

Gastrointestinal motility disorders in neurologic disease

Journal of Clinical Investigation, Год журнала: 2021, Номер 131(4)

Опубликована: Фев. 14, 2021

The extrinsic and autonomic nervous system intricately controls the major functions of gastrointestinal tract through enteric system; these include motor, secretory, sensory, storage, excretory functions. Disorders affecting function manifest primarily as abnormalities in motor (rather than secretory) Common symptoms neurologic disorders sialorrhea, dysphagia, gastroparesis, intestinal pseudo-obstruction, constipation, diarrhea, fecal incontinence. Diseases entire neural axis ranging from cerebral hemispheres to peripheral nerves can result motility disorders. most common diseases are stroke, parkinsonism, multiple sclerosis, diabetic neuropathy. Diagnosis involves identification disease its distribution, documentation segmental gut dysfunction, typically using noninvasive imaging, transit measurements, or intraluminal measurements pressure activity coordination motility. Apart treatment underlying disease, management focuses on restoration normal hydration nutrition pharmacologic neuromuscular disorder.

Язык: Английский

---

Effects on weight loss and glycemic control with SAR441255, a potent unimolecular peptide GLP-1/GIP/GCG receptor triagonist

Cell Metabolism, Год журнала: 2021, Номер 34(1), С. 59 - 74.e10

Опубликована: Дек. 20, 2021

Unimolecular triple incretins, combining the activity of glucagon-like peptide-1 (GLP-1), glucose-dependent insulinotropic polypeptide (GIP), and glucagon (GCG), have demonstrated reduction in body weight improved glucose control rodent models. We developed SAR441255, a synthetic peptide agonist GLP-1, GCG, GIP receptors, structurally based on exendin-4 sequence. SAR441255 displays high potency with balanced activation all three target receptors. In animal models, metabolic outcomes were superior to results dual GLP-1/GCG receptor agonist. Preclinical vivo positron emission tomography imaging binding GLP-1 GCG healthy subjects, glycemic during mixed-meal tolerance test impacted biomarkers for activation. Single doses well tolerated. The demonstrate that integrating into agonism provides effects loss while buffering diabetogenic risk chronic agonism.

Язык: Английский

---

Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus

Journal of Clinical Medicine, Год журнала: 2022, Номер 12(1), С. 145 - 145

Опубликована: Дек. 24, 2022

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are indicated in type 2 diabetes and obesity for their high efficacy controlling glycaemia inducing body weight loss, respectively. Patients may develop gastrointestinal adverse events (GI AEs), namely nausea, vomiting, diarrhoea and/or constipation. To minimize severity duration, healthcare providers (HCPs) patients must be aware of appropriate measures to follow while undergoing treatment. An expert panel comprising endocrinologists, nephrologists, primary care physicians, cardiologists, internists nurse educators convened across virtual meetings reach a consensus regarding these compelling recommendations. Firstly, specific guidelines provided about how the maintenance dose proceed if GI AEs during dose-escalation. Secondly, directions set avoid/minimize constipation symptoms. Clinical scenarios representing common situations daily practice, infographics useful guide both HCPs patients, included. These recommendations prevent people with T2D from withdrawing GLP-1 RAs treatment, thus benefitting superior effect on glycaemic control loss.

Язык: Английский

---

Effects of liraglutide on gastrointestinal functions and weight in obesity: A randomized clinical and pharmacogenomic trial

Obesity, Год журнала: 2022, Номер 30(8), С. 1608 - 1620

Опубликована: Июль 27, 2022

Abstract Objective This study aimed to determine the effects of a long‐acting glucagon‐like peptide‐1 (GLP‐1) receptor agonist, liraglutide, and placebo subcutaneously over 16 weeks on weight gastric functions evaluate associations single‐nucleotide polymorphisms in GLP1R (rs6923761) TCF7L2 (rs7903146) with liraglutide. Methods The conducted randomized, parallel‐group, placebo‐controlled, 16‐week trial escalated 3 mg daily 136 otherwise healthy adults obesity. Weight, emptying solids (GES), volumes, satiation, body composition measured at baseline after treatment were compared two groups using analysis covariance. Results Liraglutide ( n = 59) 65) completed treatment. Relative placebo, liraglutide increased loss 5 (both p < 0.05), slowed time half GES (T 1/2 ) 0.001), fasting volume 0.01) satiation weeks. T was positively correlated 0.001). After rs6923761 (AG/AA vs. GG) associated reduced percent fat 0.062), rs7903146 (CC CT/TT) lower 0.015). Conclusions Liraglutide, mg, induces delay reduces calorie intake. Slowing variations are

Язык: Английский

---

Semaglutide ameliorates cognition and glucose metabolism dysfunction in the 3xTg mouse model of Alzheimer's disease via the GLP-1R/SIRT1/GLUT4 pathway

Neuropharmacology, Год журнала: 2023, Номер 240, С. 109716 - 109716

Опубликована: Сен. 18, 2023

Язык: Английский

---

Fermented foods: Harnessing their potential to modulate the microbiota-gut-brain axis for mental health

Neuroscience & Biobehavioral Reviews, Год журнала: 2024, Номер 158, С. 105562 - 105562

Опубликована: Янв. 25, 2024

Over the past two decades, whole food supplementation strategies have been leveraged to target mental health. In addition, there has increasing attention on ability of gut microbes, so called psychobiotics, positively impact behaviour though microbiota-gut-brain axis. Fermented foods offer themselves as a combined microbiota modulating intervention. Indeed, they contain potentially beneficial microbial metabolites and other bioactives, which are being harnessed axis for positive benefits. This review highlights diverse nature fermented in terms raw materials used type fermentation employed, summarises their potential shape composition microbiota, brain communication pathways including immune system and, ultimately, modulate Throughout, we identify knowledge gaps challenges faced designing human studies investigating health-promoting individual or components thereof. Importantly, also suggest solutions that can advance understanding therapeutic merit

Язык: Английский

---

Glucagon-Like Peptide-1 Receptor Agonists Increase Solid Gastric Residue Rates on Upper Endoscopy Especially in Patients With Complicated Diabetes: A Case-Control Study

The American Journal of Gastroenterology, Год журнала: 2024, Номер 119(6), С. 1081 - 1088

Опубликована: Март 27, 2024

INTRODUCTION: Glucagon-like peptide-1 receptor agonists (GLP-1RAs) prescribed for weight loss and type 2 diabetes mellitus (T2DM) can delay gastric emptying, but risk factors impact on procedure outcomes remain unclear. METHODS: We compared frequency of residue upper endoscopy in patients a GLP-1RA propensity score-matched controls this retrospective case-control study consecutive undergoing endoscopic procedures over 3.5-year period. GLP-1RAs were not held before endoscopy. The presence was assessed by reviewing reports images. Predictors consequences with determined. RESULTS: In 306 users matched controls, rates significantly higher use (14% vs 4%, P < 0.01), especially T2DM insulin dependence (17% 5%, 0.01) complications (15% 2%, 0.01). Lower noted after prolonged fasting clear liquids concurrent colonoscopy (2% 11%, afternoon (4% While 22% required intubation 25% had early termination, no procedural or aspiration recorded. DISCUSSION: is associated increased endoscopy, particularly T2DM, surpassing the opiates alone. Risk highest while clear-liquid diet are protective. This does appear to translate an complications.

Язык: Английский

---